Sarepta Therapeutics (SRPT) Provides Update on ELEVIDYS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Barclays Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
April 4, 2025 12:28 PM EDTBarclays analyst Gena Wang reiterated an Overweight rating and $209.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)
The analyst comments "Key takeaways. Following the EU's temporary halt of ongoing Elevidys studies due to recent safety update, SRPT provided another update on an independent data... More
